Home › Companies › ORUKA THERAPEUTICS INC. › 2024-2025
At ORUKA THERAPEUTICS INC.'s 3 shareholder meetings in the 2024-2025 proxy season (held August 22, 2024, November 14, 2024 and June 2, 2025), 61 asset managers reported how they voted in their SEC Form N-PX filings, covering 457 separate fund positions. Their filings are grouped here into 17 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. ORUKA THERAPEUTICS INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To vote, on a non-binding, advisory basis, on the frequency of future advisory votes to approve… — the reporting funds and managers cast 100% of the shares they voted in favour (FOR divided by FOR plus AGAINST plus WITHHELD; abstained and unvoted shares are excluded because neither took a side). Fund and manager reports are combined in it and may count the same shares twice: it adds fund reports to institutional-manager reports, which can cover the same shares. It is not the company's certified result.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and ORUKA THERAPEUTICS INC.’s Form 8-K, filed June 3, 2025 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 2, 2025: 5 items on ORUKA THERAPEUTICS INC.’s Form 8-K, filed June 3, 2025: 2 elected · 2 approved · 1 without a stated outcome.
Meeting of August 22, 2024: 9 items on ORUKA THERAPEUTICS INC.’s Form 8-K, filed August 23, 2024: 9 approved.
Meeting of November 14, 2024: 2 items on ORUKA THERAPEUTICS INC.’s Form 8-K, filed November 18, 2024: 2 approved.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2024-2025 2025-2026
Explore ORUKA THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are ORUKA THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 3, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX. ORUKA THERAPEUTICS INC. reported 3 meetings in this season; each is tabulated separately below, with its own filing.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Carl Dambkowski | 26,047,914 | -- | -- | 2,291 | 732,854 | 99.9% | Elected | — |
| Elect Director: Peter Harwin | 25,935,823 | -- | -- | 114,382 | 732,854 | 99.5% | Elected | — |
| 2. Ratification of Independent Auditor Appointment | 26,781,030 | 1,848 | 181 | -- | -- | 99.9% | Approved | — |
| 3. Approval of the Compensation of our Named Executive Officers on a Non-Binding, Advisory Basis | 25,824,834 | 88,740 | 136,631 | -- | 732,854 | 99.6% | Approved | — |
| 4. Non-Binding Advisory Vote to Approve the Frequency of Future Advisory Votes to Approve Compensation for our Named Executive Officers | 54,626 | -- | 140,147 | -- | 732,854 | — | Not verified | — |
Source: ORUKA THERAPEUTICS INC., Form 8-K, filed with the SEC on June 3, 2025 — read the filing on EDGAR.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| 1. Approve (i) the issuance of shares of ARCA common stock (including the shares of ARCA common stock issuable upon conversion of ARCA Series B Preferred Stock), which will represent more than 20% of the shares of ARCA common stock outstanding immediately prio | 9,375,442 | 41,765 | 3,690 | -- | 374,562 | 99.5% | Approved | a supermajority of the shares outstanding |
| 2. Approve an amendment to the amended and restated certificate of incorporation of ARCA (the " ARCA Charter ") to increase the number of shares of ARCA common stock that ARCA is authorized to issue from 100,000,000 shares to 545,000,000 (the " Authorized Shar | 9,353,818 | 64,105 | 2,974 | -- | 374,562 | 99.3% | Approved | — |
| 3. Approve an amendment to the ARCA Charter to effect a reverse stock split of ARCA's issued and outstanding common stock at a ratio in the range between 6:1 to 12:1, inclusive, in the form attached as Annex H to the Proxy Statement/Prospectus (the " Reverse S | 9,729,049 | 64,009 | 2,401 | -- | 0 | 99.3% | Approved | — |
| 4. Approve an amendment to the ARCA Charter to reflect Delaware law provisions regarding officer exculpation, in the form attached as Annex I to the Proxy Statement/Prospectus | 8,382,645 | 1,027,657 | 10,595 | -- | 374,562 | 89% | Approved | — |
| 5. Elect the Class III director, Jacob Ma-Weaver, to ARCA's board of directors and to hold office until ARCA's 2027 annual meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal | 8,123,965 | -- | -- | 1,296,932 | 374,562 | 86% | Approved | — |
| 6. Ratify the appointment of KPMG LLP as ARCA's independent registered public accounting firm for fiscal year ending December 31, 2024, provided that PricewaterhouseCoopers LLP is expected to be appointed for that fiscal year if the Merger is completed | 9,781,878 | 11,450 | 2,131 | -- | 0 | 99.8% | Approved | — |
| 7. Approve the Oruka Therapeutics, Inc. 2024 Stock Incentive Plan (the " Oruka 2024 Incentive Plan "), which will become effective as of and contingent on the completion of the Merger | 7,060,386 | 2,338,980 | 21,531 | -- | 374,562 | 75% | Approved | — |
| 8. Approve the Oruka Therapeutics, Inc. 2024 Employee Stock Purchase Plan (the " Oruka ESPP " and together with the Oruka 2024 Incentive Plan, the " Plans "), which will become effective as of and contingent on the completion of the Merger | 7,092,970 | 2,307,499 | 20,428 | -- | 374,562 | 75% | Approved | — |
| 9. Approve, on an advisory basis, certain compensation arrangements for ARCA named executive officers that are based on or otherwise relate to the Merger | 9,321,260 | 91,368 | 8,269 | -- | 374,562 | 99.0% | Approved | — |
Source: ORUKA THERAPEUTICS INC., Form 8-K, filed with the SEC on August 23, 2024 — read the filing on EDGAR.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| 1. Approval of Conversion of Series A Preferred Stock to Common Stock | 30,598,476 | 6,026 | 1,089 | -- | -- | 99.9% | Approved | — |
| 2. Approval of an Adjournment of the Special Meeting, if Necessary or Appropriate, to Solicit Additional Proxies | 29,294,720 | 1,309,805 | 1,066 | -- | -- | 96% | Approved | — |
Source: ORUKA THERAPEUTICS INC., Form 8-K, filed with the SEC on November 18, 2024 — read the filing on EDGAR.
Each item below shows how the 61 asset managers that disclosed a ORUKA THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of ORUKA THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Meeting held June 2, 2025.
Combines 3 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Description as filed by funds: Election of Class I Directors for terms expiring in 2028: Carl Dambkowski, M.D.
ORUKA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Carl Dambkowski”): 26,047,914 for, 2,291 withheld, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected each of the two Class I directors proposed by the Company for election, to serve until the 2028 annual meeting of stockholders, and until their successors are elected and have qualified.”
Support: 99.9% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 15 asset managers below reported 6,992,575 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 5,341,711 | 0 | 0 | 0 | For |
| Vanguard | 1,011,651 | 0 | 0 | 0 | For |
| T. Rowe Price | 296,918 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 249,964 | 0 | 0 | 0 | For |
| BlackRock | 46,079 | 0 | 0 | 0 | For |
| Charles Schwab | 15,609 | 0 | 0 | 0 | For |
| John Hancock | 13,990 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 4,914 | 0 | 0 | 0 | For |
| Victory Capital | 3,633 | 0 | 0 | 0 | For |
| Aberdeen | 2,705 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 1,963 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 1,182 | 0 | 0 | 0 | For |
| ProShares | 1,140 | 0 | 0 | 0 | For |
| Equitable | 708 | 0 | 0 | 0 | For |
| State Street | 408 | 0 | 0 | 0 | For |
Meeting held June 2, 2025.
Combines 3 wordings of this item as funds reported it.
99.5% Majority: yes · of votes cast
Description as filed by funds: Election of Class I Directors for terms expiring in 2028: Peter Harwin
ORUKA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Peter Harwin”): 25,935,823 for, 114,382 withheld, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected each of the two Class I directors proposed by the Company for election, to serve until the 2028 annual meeting of stockholders, and until their successors are elected and have qualified.”
Support: 99.5% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 15 asset managers below reported 6,992,167 for, 408 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 5,341,711 | 0 | 0 | 0 | For |
| Vanguard | 1,011,651 | 0 | 0 | 0 | For |
| T. Rowe Price | 296,918 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 249,964 | 0 | 0 | 0 | For |
| BlackRock | 46,079 | 0 | 0 | 0 | For |
| Charles Schwab | 15,609 | 0 | 0 | 0 | For |
| John Hancock | 13,990 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 4,914 | 0 | 0 | 0 | For |
| Victory Capital | 3,633 | 0 | 0 | 0 | For |
| Aberdeen | 2,705 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 1,963 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 1,182 | 0 | 0 | 0 | For |
| ProShares | 1,140 | 0 | 0 | 0 | For |
| Equitable | 708 | 0 | 0 | 0 | For |
| State Street | 0 | 0 | 0 | 408 | Withhold |
Meeting held August 22, 2024.
99.5% Approved · of votes cast
Description as filed by funds: To approve (i) the issuance of shares of ARCA common stock (including the shares of ARCA common stock issuable upon conversion of ARCA Series B Preferred Stock), which will represent more than 20% of the shares of ARCA common stock outstanding immediately prior to the Merger, to stockholders of Oruka, pursuant to the terms of the Merger Agreement, a copy of which is attached as Annex A to the accompanying proxy statement/prospectus, and (ii) the change of control of ARCA resulting from the Merger, pursuant to Nasdaq Listing Rules 5635(a) and 5635(b), respectively;
ORUKA THERAPEUTICS INC.’s own tally for this item (“1. Approve (i) the issuance of shares of ARCA common stock (including the shares of ARCA common stock issuable upon conversion of ARCA Series B Preferred Stock), which will represent more than 20% of the shares of ARCA c”): 9,375,442 for, 41,765 against — passed, per its Form 8-K filed August 23, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 1: . Approve (i) the issuance of shares of ARCA common stock (including the shares of ARCA common stock issuable upon conversion of ARCA Series B Preferred Stock), which will represent more than 20% of the shares of ARCA common stock outstanding immediately prior to the Merger, to stockhol…”
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Voting standard, as the filing states it: a supermajority of the shares outstanding (“20% of the shares of ARCA common stock outstanding”).
The 3 asset managers below reported 33,675 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Aberdeen | 32,461 | 0 | 0 | 0 | For |
| Dimensional | 808 | 0 | 0 | 0 | For |
| Equitable | 406 | 0 | 0 | 0 | For |
Meeting held August 22, 2024.
86% Approved · of votes cast
Description as filed by funds: To elect the Class III director, Jacob Ma-Weaver, to ARCA's board of directors and to hold office until ARCA's 2027 annual meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal, provided that if the Merger is consummated, the approval of Proposal No. 5 will only have an effect until the completion of the Merger because the composition of ARCA's board of directors will be reconstituted upon completion of the Merger, in accordance with the Merger Agreement;
ORUKA THERAPEUTICS INC.’s own tally for this item (“5. Elect the Class III director, Jacob Ma-Weaver, to ARCA's board of directors and to hold office until ARCA's 2027 annual meeting of stockholders and until his successor has been duly elected and qualified, or until his”): 8,123,965 for, 1,296,932 withheld — passed, per its Form 8-K filed August 23, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “This proposal was approved by the requisite vote of ARCA's stockholders.”
Support: 86% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 3 asset managers below reported 33,675 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Aberdeen | 0 | 0 | 0 | 32,461 | Withhold |
| Dimensional | 0 | 0 | 0 | 808 | Withhold |
| Equitable | 0 | 0 | 0 | 406 | Withhold |
Meeting held August 22, 2024.
89% Approved · of votes cast
Description as filed by funds: To approve an amendment to the ARCA Charter to reflect Delaware law provisions regarding officer exculpation, in the form attached as Annex I to the accompanying proxy statement/prospectus;
ORUKA THERAPEUTICS INC.’s own tally for this item (“4. Approve an amendment to the ARCA Charter to reflect Delaware law provisions regarding officer exculpation, in the form attached as Annex I to the Proxy Statement/Prospectus”): 8,382,645 for, 1,027,657 against — passed, per its Form 8-K filed August 23, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “This proposal was approved by the requisite vote of the Company's stockholders.”
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 3 asset managers below reported 33,675 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Aberdeen | 32,461 | 0 | 0 | 0 | For |
| Dimensional | 808 | 0 | 0 | 0 | For |
| Equitable | 406 | 0 | 0 | 0 | For |
Meeting held August 22, 2024.
99.3% Approved · of votes cast
Description as filed by funds: To approve an amendment to the amended and restated certificate of incorporation of ARCA (the "ARCA Charter") to increase the number of shares of ARCA common stock that ARCA is authorized from 100,000,000 to issue to 545,000,000, in the form attached as Annex G to the accompanying proxy statement/prospectus;
ORUKA THERAPEUTICS INC.’s own tally for this item (“2. Approve an amendment to the amended and restated certificate of incorporation of ARCA (the " ARCA Charter ") to increase the number of shares of ARCA common stock that ARCA is authorized to issue from 100,000,000 shar”): 9,353,818 for, 64,105 against — passed, per its Form 8-K filed August 23, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “This proposal was approved by the requisite vote of ARCA's stockholders.”
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 3 asset managers below reported 33,675 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Aberdeen | 32,461 | 0 | 0 | 0 | For |
| Dimensional | 808 | 0 | 0 | 0 | For |
| Equitable | 406 | 0 | 0 | 0 | For |
Meeting held August 22, 2024.
99.3% Approved · of votes cast
Description as filed by funds: To approve an amendment to the ARCA Charter to effect a reverse stock split of ARCA's issued and outstanding common stock at a ratio in the range between 6:1 to 12:1, inclusive, in the form attached as Annex H to the accompanying proxy statement/prospectus, if deemed necessary by ARCA and Oruka, with the final ratio and effectiveness of such amendment and the abandonment of such amendment to be mutually agreed by ARCA's board of directors and Oruka's board of directors prior to the First Effective Time or, if the Nasdaq Stock Issuance Proposal is not approved by ARCA stockholders, determined solely by ARCA's board of directors;
ORUKA THERAPEUTICS INC.’s own tally for this item (“3. Approve an amendment to the ARCA Charter to effect a reverse stock split of ARCA's issued and outstanding common stock at a ratio in the range between 6:1 to 12:1, inclusive, in the form attached as Annex H to the Pro”): 9,729,049 for, 64,009 against — passed, per its Form 8-K filed August 23, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “This proposal was approved by the requisite vote of ARCA's stockholders.”
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 3 asset managers below reported 33,675 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Aberdeen | 32,461 | 0 | 0 | 0 | For |
| Dimensional | 808 | 0 | 0 | 0 | For |
| Equitable | 406 | 0 | 0 | 0 | For |
Meeting held November 14, 2024.
96% Approved · of votes cast
Description as filed by funds: To approve an adjournment of the Special Meeting, if necessary or appropriate, to solicit additional proxies.
ORUKA THERAPEUTICS INC.’s own tally for this item (“2. Approval of an Adjournment of the Special Meeting, if Necessary or Appropriate, to Solicit Additional Proxies”): 29,294,720 for, 1,309,805 against — passed, per its Form 8-K filed November 18, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Approval of an Adjournment of the Special Meeting, if Necessary or Appropriate, to Solicit Additional Proxies The Company's stockholders approved an adjournment of the Special Meeting, if necessary or appropriate, to solicit additional proxies.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 10 asset managers below reported 4,604,703 for, 1,199,011 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 4,328,904 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 1,179,389 | 0 | 0 | Against |
| FRANKLIN STRATEGIC SERIES | 249,964 | 0 | 0 | 0 | For |
| Vanguard | 20,898 | 0 | 0 | 0 | For |
| John Hancock | 0 | 18,111 | 0 | 0 | Against |
| Aberdeen | 2,705 | 0 | 0 | 0 | For |
| BlackRock | 2,127 | 0 | 0 | 0 | For |
| Equitable | 32 | 1,511 | 0 | 0 | Against |
| Charles Schwab | 72 | 0 | 0 | 0 | For |
| Dimensional | 1 | 0 | 0 | 0 | For |
Meeting held November 14, 2024.
Combines 2 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Description as filed by funds: To approve, in accordance with Nasdaq Listing Rule 5635(d), the issuance of shares of the Company's common stock upon conversion of the Company's Series A Non-Voting Convertible Preferred Stock, par value $0.001 per share, issued in September 2024.
ORUKA THERAPEUTICS INC.’s own tally for this item (“1. Approval of Conversion of Series A Preferred Stock to Common Stock”): 30,598,476 for, 6,026 against — passed, per its Form 8-K filed November 18, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Approval of Conversion of Series A Preferred Stock to Common Stock The Company's stockholders approved the issuance of shares of the Company's common stock upon conversion of the Company's Series A Non-Voting Convertible Preferred Stock, par value $0.001 per share, issued in September 2024.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 10 asset managers below reported 5,803,714 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 4,328,904 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,179,389 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 249,964 | 0 | 0 | 0 | For |
| Vanguard | 20,898 | 0 | 0 | 0 | For |
| John Hancock | 18,111 | 0 | 0 | 0 | For |
| Aberdeen | 2,705 | 0 | 0 | 0 | For |
| BlackRock | 2,127 | 0 | 0 | 0 | For |
| Equitable | 1,543 | 0 | 0 | 0 | For |
| Charles Schwab | 72 | 0 | 0 | 0 | For |
| Dimensional | 1 | 0 | 0 | 0 | For |
Meeting held August 22, 2024.
100% of fund votes cast · no official result
Description as filed by funds: To approve an adjournment of the ARCA special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal; and
The 3 asset managers below reported 33,675 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Aberdeen | 32,461 | 0 | 0 | 0 | For |
| Dimensional | 808 | 0 | 0 | 0 | For |
| Equitable | 406 | 0 | 0 | 0 | For |
Meeting held August 22, 2024.
75% Approved · of votes cast
Description as filed by funds: To approve the Oruka Therapeutics, Inc. 2024 Employee Stock Purchase Plan;
ORUKA THERAPEUTICS INC.’s own tally for this item (“8. Approve the Oruka Therapeutics, Inc. 2024 Employee Stock Purchase Plan (the " Oruka ESPP " and together with the Oruka 2024 Incentive Plan, the " Plans "), which will become effective as of and contingent on the compl”): 7,092,970 for, 2,307,499 against — passed, per its Form 8-K filed August 23, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “This proposal was approved by the requisite vote of ARCA's stockholders.”
Support: 75% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 3 asset managers below reported 33,675 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Aberdeen | 0 | 32,461 | 0 | 0 | Against |
| Dimensional | 0 | 808 | 0 | 0 | Against |
| Equitable | 0 | 406 | 0 | 0 | Against |
Meeting held August 22, 2024.
0% of fund votes cast · no official result
Description as filed by funds: To approve the Oruka Therapeutics, Inc. 2024 Stock Incentive Plan;
The 3 asset managers below reported 33,675 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Aberdeen | 0 | 32,461 | 0 | 0 | Against |
| Dimensional | 0 | 808 | 0 | 0 | Against |
| Equitable | 0 | 406 | 0 | 0 | Against |
Meeting held June 2, 2025.
Combines 5 wordings of this item as funds reported it.
100% Fund and manager reports combined; may count the same shares twice · no official result
Description as filed by funds: To vote, on a non-binding, advisory basis, on the frequency of future advisory votes to approve compensation for our named executive officers.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 0 | 0 | 0 | 0 | -- |
| Vanguard | 0 | 0 | 0 | 0 | -- |
| T. Rowe Price | 0 | 0 | 0 | 0 | -- |
| FRANKLIN STRATEGIC SERIES | 0 | 0 | 0 | 0 | -- |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| Charles Schwab | 0 | 0 | 0 | 0 | -- |
| John Hancock | 0 | 0 | 0 | 0 | -- |
| MUTUAL FUND SERIES TRUST | 4,914 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 0 | 0 | 0 | -- |
| Aberdeen | 0 | 0 | 0 | 0 | -- |
| Exchange Place Advisors Trust | 0 | 0 | 0 | 0 | -- |
| AIG/SunAmerica | 0 | 0 | 0 | 0 | -- |
| ProShares | 0 | 0 | 0 | 0 | -- |
| Equitable | 0 | 0 | 0 | 0 | -- |
| State Street | 0 | 0 | 0 | 0 | -- |
Fund voting reports, all 15 managers: 4,914 for, 6,987,661 1 year.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 0 | 0 | 0 | 0 | -- |
| Fairmount Funds Management LLC | 0 | 0 | 0 | 0 | -- |
| Deep Track Capital, LP | 0 | 0 | 0 | 0 | -- |
| BRAIDWELL LP | 0 | 0 | 0 | 0 | -- |
| Commodore Capital LP | 0 | 0 | 0 | 0 | -- |
| FRANKLIN ADVISERS INC | 0 | 0 | 0 | 0 | -- |
| Blackstone Inc. | 0 | 0 | 0 | 0 | -- |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| SR ONE CAPITAL MANAGEMENT, LP | 430,330 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 0 | 0 | -- |
| Woodline Partners LP | 0 | 0 | 0 | 0 | -- |
| Affinity Asset Advisors, LLC | 0 | 0 | 0 | 0 | -- |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 0 | 0 | 0 | -- |
| Avidity Partners Management LP | 0 | 0 | 0 | 0 | -- |
| Point72 | 0 | 0 | 0 | 0 | -- |
| Redmile Group, LLC | 0 | 0 | 0 | 0 | -- |
| SILVERARC CAPITAL MANAGEMENT, LLC | 0 | 0 | 0 | 0 | -- |
| Candriam S.C.A. | 0 | 0 | 0 | 0 | -- |
| ADAR1 Capital Management, LLC | 0 | 0 | 0 | 0 | -- |
| Northern Trust | 0 | 0 | 0 | 0 | -- |
| UniSuper Management Pty Ltd | 0 | 0 | 0 | 0 | -- |
| State Street | 0 | 0 | 0 | 0 | -- |
| RTW INVESTMENTS, LP | 0 | 0 | 0 | 0 | -- |
| KENNEDY CAPITAL MANAGEMENT LLC | 0 | 0 | 0 | 0 | -- |
| Charles Schwab | 0 | 0 | 0 | 0 | -- |
Institutional-manager reports, all 50 managers: 430,330 for, 18,339,050 1 year. Showing the 25 largest; every one is in the interactive database (link above).
Meeting held June 2, 2025.
Combines 4 wordings of this item as funds reported it.
99.6% Approved · of votes cast
Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation of our named executive officers.
ORUKA THERAPEUTICS INC.’s own tally for this item (“3. Approval of the Compensation of our Named Executive Officers on a Non-Binding, Advisory Basis”): 25,824,834 for, 88,740 against — passed, per its Form 8-K filed June 3, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3: Approval of the Compensation of our Named Executive Officers on a Non-Binding, Advisory Basis The Company's stockholders approved, by non-binding advisory vote, the compensation of our named executive officers as disclosed in the Proxy Statement.”
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 5,341,711 | 0 | 0 | 0 | For |
| Vanguard | 1,011,651 | 0 | 0 | 0 | For |
| T. Rowe Price | 296,918 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 249,964 | 0 | 0 | 0 | For |
| BlackRock | 46,079 | 0 | 0 | 0 | For |
| Charles Schwab | 15,609 | 0 | 0 | 0 | For |
| John Hancock | 13,990 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 4,914 | 0 | 0 | 0 | For |
| Victory Capital | 3,633 | 0 | 0 | 0 | For |
| Aberdeen | 2,705 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 1,963 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 1,182 | 0 | 0 | 0 | For |
| ProShares | 1,140 | 0 | 0 | 0 | For |
| Equitable | 708 | 0 | 0 | 0 | For |
| State Street | 408 | 0 | 0 | 0 | For |
Fund voting reports, all 15 managers: 6,992,575 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 5,446,208 | 0 | 0 | 0 | For |
| Fairmount Funds Management LLC | 3,371,922 | 0 | 0 | 0 | For |
| Deep Track Capital, LP | 1,683,848 | 0 | 0 | 0 | For |
| BRAIDWELL LP | 1,572,426 | 0 | 0 | 0 | For |
| Commodore Capital LP | 1,403,730 | 0 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 720,547 | 0 | 0 | 0 | For |
| Blackstone Inc. | 642,844 | 0 | 0 | 0 | For |
| BlackRock | 495,855 | 0 | 0 | 0 | For |
| SR ONE CAPITAL MANAGEMENT, LP | 430,330 | 0 | 0 | 0 | For |
| T. Rowe Price | 405,832 | 0 | 0 | 0 | For |
| Woodline Partners LP | 390,633 | 0 | 0 | 0 | For |
| Affinity Asset Advisors, LLC | 375,246 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 352,583 | 0 | 0 | 0 | For |
| Avidity Partners Management LP | 352,124 | 0 | 0 | 0 | For |
| Point72 | 330,000 | 0 | 0 | 0 | For |
| Redmile Group, LLC | 234,094 | 0 | 0 | 0 | For |
| SILVERARC CAPITAL MANAGEMENT, LLC | 150,183 | 0 | 0 | 0 | For |
| Candriam S.C.A. | 0 | 79,698 | 0 | 0 | Against |
| ADAR1 Capital Management, LLC | 73,959 | 0 | 0 | 0 | For |
| Northern Trust | 58,285 | 0 | 0 | 0 | For |
| UniSuper Management Pty Ltd | 50,000 | 0 | 0 | 0 | For |
| State Street | 32,509 | 0 | 0 | 0 | For |
| RTW INVESTMENTS, LP | 19,923 | 0 | 0 | 0 | For |
| KENNEDY CAPITAL MANAGEMENT LLC | 17,996 | 0 | 0 | 0 | For |
| Charles Schwab | 15,609 | 0 | 0 | 0 | For |
Institutional-manager reports, all 48 managers: 18,688,028 for, 81,264 against. Showing the 25 largest; every one is in the interactive database (link above).
Meeting held August 22, 2024.
99.0% Approved · of votes cast
Description as filed by funds: To approve, on an advisory basis, certain compensation arrangements for ARCA named executive officers that are based on or otherwise relate to the Merger;
ORUKA THERAPEUTICS INC.’s own tally for this item (“9. Approve, on an advisory basis, certain compensation arrangements for ARCA named executive officers that are based on or otherwise relate to the Merger”): 9,321,260 for, 91,368 against — passed, per its Form 8-K filed August 23, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “This proposal was approved by the requisite vote of ARCA's stockholders.”
Support: 99.0% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Aberdeen | 0 | 32,461 | 0 | 0 | Against |
| Dimensional | 808 | 0 | 0 | 0 | For |
| Equitable | 406 | 0 | 0 | 0 | For |
Fund voting reports, all 3 managers: 1,214 for, 32,461 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | 949,251 | 0 | 0 | 0 | For |
| VR Adviser, LLC | 866,375 | 0 | 0 | 0 | For |
| Janus Henderson | 429,586 | 0 | 0 | 0 | For |
| Renaissance | 32,787 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 32,461 | 0 | 0 | Against |
| Ancora Advisors LLC | 1,000 | 0 | 0 | 0 | For |
| Point72 | 897 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 535 | 0 | 0 | 0 | For |
| TOCQUEVILLE ASSET MANAGEMENT L.P. | 109 | 0 | 0 | 0 | For |
| Two Sigma | 47 | 0 | 0 | 0 | For |
Institutional-manager reports, all 10 managers: 2,280,587 for, 32,461 against.
Meeting held June 2, 2025.
99.9% Approved · of votes cast
Description as filed by funds: To ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm of Oruka Therapeutics, Inc. for its fiscal year ending December 31, 2025.
ORUKA THERAPEUTICS INC.’s own tally for this item (“2. Ratification of Independent Auditor Appointment”): 26,781,030 for, 1,848 against — passed, per its Form 8-K filed June 3, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2: Ratification of Independent Auditor Appointment The Company's stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 15 asset managers below reported 6,992,575 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 5,341,711 | 0 | 0 | 0 | For |
| Vanguard | 1,011,651 | 0 | 0 | 0 | For |
| T. Rowe Price | 296,918 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 249,964 | 0 | 0 | 0 | For |
| BlackRock | 46,079 | 0 | 0 | 0 | For |
| Charles Schwab | 15,609 | 0 | 0 | 0 | For |
| John Hancock | 13,990 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 4,914 | 0 | 0 | 0 | For |
| Victory Capital | 3,633 | 0 | 0 | 0 | For |
| Aberdeen | 2,705 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 1,963 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 1,182 | 0 | 0 | 0 | For |
| ProShares | 1,140 | 0 | 0 | 0 | For |
| Equitable | 708 | 0 | 0 | 0 | For |
| State Street | 408 | 0 | 0 | 0 | For |
Meeting held August 22, 2024.
99.8% Approved · of votes cast
Description as filed by funds: To ratify the appointment of KPMG LLP as ARCA's independent registered public accounting firm for fiscal year ending December 31, 2024, provided that PricewaterhouseCoopers LLP is expected to be appointed for that fiscal year if the Merger is completed;
ORUKA THERAPEUTICS INC.’s own tally for this item (“6. Ratify the appointment of KPMG LLP as ARCA's independent registered public accounting firm for fiscal year ending December 31, 2024, provided that PricewaterhouseCoopers LLP is expected to be appointed for that fiscal”): 9,781,878 for, 11,450 against — passed, per its Form 8-K filed August 23, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “This proposal was approved by the requisite vote of ARCA's stockholders.”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 3 asset managers below reported 33,675 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Aberdeen | 32,461 | 0 | 0 | 0 | For |
| Dimensional | 808 | 0 | 0 | 0 | For |
| Equitable | 406 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 37,440,510 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 14.27% |
| 2 | Vanguard | 2.70% |
| 3 | T. Rowe Price | 0.79% |
| 4 | FRANKLIN STRATEGIC SERIES | 0.67% |
| 5 | BlackRock | 0.12% |
| 6 | Charles Schwab | 0.04% |
| 7 | John Hancock | 0.04% |
| 8 | MUTUAL FUND SERIES TRUST | 0.01% |
| 9 | Victory Capital | <0.01% |
| 10 | Aberdeen | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 14.55% |
| 2 | Fairmount Funds Management LLC | 9.01% |
| 3 | Deep Track Capital, LP | 4.50% |
| 4 | BRAIDWELL LP | 4.20% |
| 5 | Commodore Capital LP | 3.75% |
| 6 | FRANKLIN ADVISERS INC | 1.92% |
| 7 | Blackstone Inc. | 1.72% |
| 8 | BlackRock | 1.32% |
| 9 | SR ONE CAPITAL MANAGEMENT, LP | 1.15% |
| 10 | T. Rowe Price | 1.08% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Fairmount Funds Management LLC | — | 13D |
| Entities affiliated with Fairmount Funds Management LLC | — | DEF14A |
| Peter Harwin | — | DEF14A |
| FMR LLC | — | DEF14A |
| FMR (Fidelity) | — | 13F |
| Venrock Healthcare Capital Partners III, L.P. | — | 13G |
| Entities affiliated with Venrock Healthcare Capital Partners | — | DEF14A |
| VIKING GLOBAL INVESTORS LP | — | 13G |
| Deep Track Capital, LP | — | 13G |
| RTW Investments, LP | — | 13G |
Percentages above are of 37,440,510 shares outstanding, as reported by ORUKA THERAPEUTICS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ORUKA THERAPEUTICS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
ORUKA THERAPEUTICS INC. proxy season coverage: 2024-2025 (this page) · 2025-2026.
proxyvotesnow.com, “ORUKA THERAPEUTICS (ORKA) 2024-2025 Annual & Special Meetings”, https://proxyvotesnow.com/company/oruka-therapeutics-inc/2025 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.